Tag: agent

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

Highland, Indiana, July 07, 2025 (GLOBE NEWSWIRE) -- REsimpli, a leading all-in-one AI CRM for Real Estate Investors, is thrilled to announce the launch of its REsimpli 5.0 release that introduces 8 powerful AI Agent tools and a List Pulling Feature that help investors pull off-market properties with necessary filters for the best results. These tools are designed to automate communication, reduce response times, and dramatically improve conversion rates.

Celebration, FL, July 07, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today announced the launch of My Agent Account Version 4.0, a major enhancement to the Company’s proprietary agent platform. The new version, which went live on July 1, 2025, features a fully integrated Transaction Management module that is intended to deliver significant cost savings to the Company by improving efficiency, reducing manual processes, and eliminating reliance on expensive third-party systems.

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

SHREWSBURY, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a blockchain infrastructure project focused on AI-native applications, has completed all 15 presale phases without delays and is now entering its Bonus Round. The project has raised $21 million to date, with tokens continuing to be available at a fixed price of $0.007.

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

AS LHV Group announces that during the period 27.06-03.07.2025, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.

FREMONT, Calif, July 03, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants.